Moderna begins late-stage study of RSV vaccine using mRNA technology
Moderna begins late-stage study of RSV vaccine using mRNA technology
February 22, 2022; 9:02 AM EST
(Reuters) – Moderna Inc (MRNA.O) said on Tuesday it had begun a late-stage study of its vaccine for Respiratory Syncytial Virus (RSV) based on the same technology used to develop its COVID-19 shots.
The only approved product using messenger RNA (mRNA) is COVID-19 vaccine, but Moderna and rival Pfizer (PFE.N) are rushing to tap the potential of the technology to target diseases such as shingles and cancer.
Moderna is developing a vaccine for flu using mRNA technology and said on Friday it would develop three more shots, including one for viral infection shingles.
RSV is a common respiratory virus that generally causes cold-like symptoms, but which can be serious for young children and older adults.
Moderna made the decision to begin the late-stage portion of the study after an independent review of preliminary mid-stage data that suggested the vaccine has an acceptable safety profile in older adults.
Our Standards: The Thomson Reuters Trust Principles.
Reuters source: